Charles Schwab Investment Management Inc. boosted its holdings in shares of Pacira Biosciences Inc (NASDAQ:PCRX) by 3.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 298,329 shares of the company’s stock after buying an additional 10,153 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.72% of Pacira Biosciences worth $12,975,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of the stock. Smith Asset Management Group LP increased its position in Pacira Biosciences by 181.2% in the 2nd quarter. Smith Asset Management Group LP now owns 27,131 shares of the company’s stock worth $1,180,000 after purchasing an additional 17,481 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of Pacira Biosciences by 156.1% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 52,630 shares of the company’s stock worth $2,313,000 after acquiring an additional 32,082 shares during the period. Geode Capital Management LLC lifted its position in shares of Pacira Biosciences by 7.4% in the 4th quarter. Geode Capital Management LLC now owns 516,774 shares of the company’s stock worth $22,231,000 after acquiring an additional 35,635 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Pacira Biosciences by 1,036.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 158,013 shares of the company’s stock worth $6,942,000 after acquiring an additional 144,108 shares during the period. Finally, Boston Private Wealth LLC bought a new stake in shares of Pacira Biosciences in the 2nd quarter worth approximately $217,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.
In other news, insider Kristen Marie Williams sold 6,252 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $39.49, for a total value of $246,891.48. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO David M. Stack sold 12,849 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $39.15, for a total value of $503,038.35. The disclosure for this sale can be found here. 5.80% of the stock is owned by company insiders.
PCRX stock traded up $0.92 during midday trading on Friday, reaching $37.69. 447,930 shares of the company’s stock traded hands, compared to its average volume of 1,266,168. The company has a 50-day simple moving average of $37.54 and a two-hundred day simple moving average of $40.87. The company has a market cap of $1.53 billion, a price-to-earnings ratio of 129.97, a PEG ratio of 1.69 and a beta of 1.11. Pacira Biosciences Inc has a 1-year low of $34.64 and a 1-year high of $55.00. The company has a quick ratio of 4.12, a current ratio of 4.75 and a debt-to-equity ratio of 0.99.
Pacira Biosciences (NASDAQ:PCRX) last released its earnings results on Thursday, August 8th. The company reported $0.41 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.27. Pacira Biosciences had a return on equity of 8.62% and a net margin of 2.04%. The company had revenue of $102.60 million during the quarter, compared to analysts’ expectations of $99.92 million. During the same period last year, the firm earned $0.24 EPS. The business’s revenue for the quarter was up 22.0% on a year-over-year basis. Equities research analysts forecast that Pacira Biosciences Inc will post 0.64 EPS for the current year.
A number of brokerages have commented on PCRX. Wedbush set a $85.00 price objective on Pacira Biosciences and gave the stock a “buy” rating in a research report on Friday, June 28th. BidaskClub cut Pacira Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, October 3rd. Stifel Nicolaus set a $42.00 target price on Pacira Biosciences and gave the stock a “hold” rating in a report on Friday, August 9th. Jefferies Financial Group set a $60.00 target price on Pacira Biosciences and gave the stock a “buy” rating in a report on Tuesday. Finally, BMO Capital Markets dropped their target price on Pacira Biosciences from $46.00 to $43.00 and set a “market perform” rating for the company in a report on Friday, August 9th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $55.00.
About Pacira Biosciences
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.
Further Reading: Cost of Debt
Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.